Affectis has partnered its AFC-08 program to Phenoquest AG.
AFC-08 is a monoclonal antibody with high binding affinity to the human TMEFF2 protein. TMEFF2 expression is restricted to specific areas of the brain associated with depressive behaviour. Inactivation of TMEFF2 results in antidepressant effects. If successful, AFC-08 would be the first biological drug used for the treatment of psychiatric disorders and could have prophylactic use and relapse prevention potential in depression.
Affectis is entitled to milestones and royalty payments from Phenoquest upon reaching certain development and commercial events.